Halozyme Therapeutics posts strong Q1 2025 earnings with 35% revenue growth, robust pipeline, and rising royalties.

President Donald Trump says he’ll sign an executive order on Monday intended to lower the cost of drugs in the U.S.

Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2025 results , but sales fell by 1.6% year on year to $15.53 ...

Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an appealing treatment for advanced melanoma.

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Its biggest would-be competitor is ivonescimab, a medicine being developed in the U.S. by Summit Therapeutics. It delivered positive clinical trial results in China in a phase 3 study in which it went ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...

The firm is studying the combination in the first-line setting for head and neck cancer patients who had a PD-L1 combined positive score of less than 1.

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...

Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after ...

Merck is injecting $1 billion into a new facility in Wilmington, Delaware to amp up U.S. drug production, especially for its ...